American Conference for the Treatment of HIV

May 20 - 23, 2010 • Hyatt Regency Denver
Denver, CO

The educational activity is jointly sponsored by the American Academy of CME, Inc. and the Foundation for the American Conference for the Treatment of HIV. The American Conference for the Treatment of HIV (ACTHIV) is supported by funding from the Office of AIDS Research of the National Institutes of Health. The educational portion of ACTHIV is supported by educational grants from Bristol-Myers Squibb and Gilead.
The American Conference for the Treatment of HIV is supported by funding from the Office of AIDS Research on the National Institutes of Health.

The educational component of ACTHIV 2010 is additionally supported by educational grants from:

- Bristol-Myers Squibb
- Gilead

Advancing Therapeutics. Improving Lives.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference Leadership</td>
<td>2</td>
</tr>
<tr>
<td>About ACTHIV 2010</td>
<td>4</td>
</tr>
<tr>
<td>Welcome from the Program Committee Co-Chairs</td>
<td>5</td>
</tr>
<tr>
<td>Welcome from the President of the Board</td>
<td>6</td>
</tr>
<tr>
<td>Schedule at a Glance</td>
<td>7</td>
</tr>
<tr>
<td>Registration</td>
<td>8</td>
</tr>
<tr>
<td>Meals &amp; Refreshments</td>
<td>8</td>
</tr>
<tr>
<td>Special Events</td>
<td>8</td>
</tr>
<tr>
<td>General Information</td>
<td>9</td>
</tr>
<tr>
<td>Transportation and Parking</td>
<td>9</td>
</tr>
<tr>
<td>Presenter Information</td>
<td>10</td>
</tr>
<tr>
<td>Accreditation</td>
<td>11</td>
</tr>
<tr>
<td>Exhibit Hall</td>
<td>12</td>
</tr>
<tr>
<td>Conference Agenda</td>
<td>13</td>
</tr>
<tr>
<td>Poster Sessions</td>
<td>18</td>
</tr>
<tr>
<td>Faculty</td>
<td>21</td>
</tr>
<tr>
<td>Financial and Off-Label Disclosure Information</td>
<td>22</td>
</tr>
</tbody>
</table>
LEADERSHIP

BOARD OF DIRECTORS

President
Douglas J. Ward, MD, FACP
Dupont Circle Physicians Group
Washington, DC

Melanie Thompson, MD
AIDS Research Consortium of Atlanta
Atlanta, GA

Secretary/Treasurer
Sharon Lee, MD
Southwest Boulevard Family Health Care Services
Kansas City, KS

2009 – 2010 PROGRAM COMMITTEE

Co-Chair
Kathleen E. Squires, MD
Jefferson Medical College
Thomas Jefferson University
Philadelphia, PA

Co-Chair
John T. Brooks, MD
Centers for Disease Control and Prevention
Atlanta, GA

Erika Aaron, CRNP, MSN
Drexel University College of Medicine
Division of Infectious Diseases and HIV Medicine
Philadelphia, PA

Harold Henderson, MD
Division of Infectious Diseases
University of Mississippi Medical Center
Jackson, MS

Laura Armas-Kolostroubis, MD
Texas/Oklahoma AIDS Education and Training Center
Dallas, TX

John JD Juchniewicz, MCIS
American Academy of CME, Inc.
Skillman, NJ

Arlene Bardeguez, MD, MPH
New Jersey Medical School
Department of Obstetrics, Gynecology & Women’s Health
Guttenberg, NJ

Natalie Kirkwood, RN, BSN, JD
American Academy of CME, Inc
Skillman, NJ

Steve Deeks, MD
University of California, San Francisco
San Francisco, CA

Harry Lampiris, MD
San Francisco VA Medical Center / UCSF
San Francisco, CA

Lisa Fitzpatrick, MD, MPH
Howard University
Washington, DC

Kenneth Lichtenstein, MD
National Jewish Medical and Research Center
Denver, CO

Donna Futterman, MD
Adolescent AIDS Program
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

Tonia Poteat, MMSc, MPH, PA-C
Chase Brexton Health Services
Baltimore, MD

Anita Radix MD, MPH
Callen Lorde Community Health Center
New York, NY
M. Keith Rawlings, MD
Peabody Health Center
AIDS Arms, Inc.
Dallas, TX

David Rimland, MD
VA Medical Center
Decatur, GA

William R. Short, MD, MPH
Jefferson Medical College
Thomas Jefferson University
Philadelphia, PA

Glenn Treisman, MD, PhD
Johns Hopkins University School of Medicine
Department of Psychiatry and Behavioral Sciences /
Department of Medicine
Baltimore, MD

Barbara A. Young, MSW, LCSW, LCADC, SAC
American Academy of CME, Inc.
Skillman, NJ

This conference is held in scientific collaboration with the following federal agencies and their representatives:

Songhai Barclift, MD
Health Resources and Services Administration
HIV/AIDS Bureau
Rockville, MD

Gina Brown, MD
National Institutes of Health
Office of AIDS Research
Bethesda, MD

Laura Cheever, MD
Health Resources and Services Administration
HIV/AIDS Bureau
Rockville, MD

Robert Eisinger, PhD
National Institutes of Health
Office of AIDS Research
Bethesda, MD

Newton Kendig, RADM
Federal Bureau of Prisons
Washington, DC

Jag Khalsa, PhD
National Institute on Drug Abuse, NIH
Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMC)
Bethesda, MD

Peter Kim, MD
National Institute for Allergy and Infectious Diseases
National Institutes of Health
HIV Research Branch/TRP
Bethesda, MD

Lynne Mofenson, MD
National Institute of Child Health and Human Development
Pediatric, Adolescent & Maternal AIDS Branch
Eunice Kennedy Shriver
Rockville, MD

Mostafa Nokta, MD, MPH
AIDS Cancer Clinical Program
National Cancer Institute
Office of HIV and AIDS Malignancy
Bethesda, MD

Ronald Valdiserri, MD, MPH
Public Health Strategic Health Care Group
Department of Veterans Affairs
Washington, DC

Christopher Gordon, PhD
National Institutes of Health
National Institutes of Mental Health
Bethesda, MD
The Foundation for the American Conference for the Treatment of HIV is a non-profit organization established in 2006 for the sole purpose of producing and executing a treatment education conference for frontline HIV care providers. The mission of the foundation and the goals of the conference are:

- To conduct a state-of-the-science meeting for primary clinical care providers (physicians, nurses, physician assistants, nurse practitioners, psychologists, pharmacists, et. al.)
- To translate the latest developments in HIV clinical science to the delivery of medical care to persons with HIV infection
- To learn from active clinical care providers about their experience in treating persons with HIV infection in order to advance clinical care and research.

**Target Audience**

ACTHIV is targeted toward frontline providers of persons at risk of or with HIV infection including: physicians (both specialists and primary care/family medicine), nurses, pharmacists, and medical case managers (including social workers). Psychologists, mental health and substance abuse workers, treatment advocates, treatment educators, and other healthcare professionals involved in caring for those infected with HIV may also benefit from participation.

**Global Learning Objectives**

At the conclusion of the conference, participants will be able to:

- Design treatment regimens for both treatment-naïve and -experienced patients based on recent changes to the antiretroviral guidelines
- Implement strategies to promote adherence and retention in care
- Utilize antiretrovirals for pre- and post-HIV-exposure prophylaxis based on best practices
- Assess the role of immune activation on the complications related to HIV disease
- Implement clinical monitoring to screen and manage common co-morbidities in people living with HIV/AIDS
- Employ evidence-based strategies for diagnosing and managing patients with HIV and cancer
- Diagnose and manage patients with concurrent HIV and mental illness or addiction with special attention to managing drug interactions with psychotropics agents and the timing of psychiatric referral
- Adopt and implement prevention strategies for special populations, including youth, men who have sex with men, transgenders, immigrants and those who are incarcerated or homeless, given the unique risks of these populations
- Modify evaluation and treatment approaches to ensure culturally competent delivery of HIV-related health services to special populations, including youth, men who have sex with men, transgenders, immigrants and those who are incarcerated or homeless, based on the needs of these populations

**Additional Objectives**

The following additional global objectives were identified for *HIV: The Basics*, which is targeted to those providers who are relatively new to HIV care, as well as those who have not provided care to persons with HIV infection in some time.

- Appropriately test and diagnose HIV infection
- Properly assess the immune status of HIV-infected persons entering care
- Initiate effective highly active antiretroviral therapy HIV-infected persons.

Learning objectives for individual talks can be found on the speaker evaluation form.
Welcome from the Program Committee Co-Chairs

Welcome to the American Conference for the Treatment of HIV (ACTHIV).

We are delighted that you have decided to join us in exploring the excitement and challenges of caring for people living with HIV infection. This is our fourth meeting following three prior successful events in Atlanta, Dallas and Denver. HIV care and treatment continues to evolve with new scientific discoveries, new drug classes and treatment breakthroughs with associated management challenges, and we are pleased to be meeting again to have this opportunity to help keep you, the nation’s frontline HIV care providers, up to date with the latest developments in the care and treatment of persons living with HIV infection.

The news since our last meeting remains both daunting and encouraging. Numerous recommendations on when to start antiretroviral therapy have changed, moving the CD4 cell count at which initiation is recommended higher. Updated guidelines on the prevention and treatment of opportunistic infections have also been seen in the past year. As HIV testing has become more routine, the number of patients who now know their status and seek treatment is beginning to increase more quickly. Disparities in HIV incidence and transmission remain a challenge, especially in certain populations, such as men who have sex with men and women. Data from vaccine and pre-exposure prophylaxis trials remind us that our field still faces many challenges although data from microbicide trials suggest we might be on the verge of making significant headway in primary HIV prevention. The clinical consequences of longer survival continue to emerge with important new and actionable data on cardiovascular disease, bone health, malignancies, viral hepatitis, neurocognition and maintaining a high quality of life. Although exciting newer treatment options have improved the quality and quantity of life for many persons living with HIV infection, the benefits are not shared by all due to continued inequities in access to care, differential treatment adherence rates, and different burdens in pre-existing conditions and side effects of treatment. As persons living with HIV infection continue to live longer lives, we are presented with the challenge of managing HIV infection along with the medical problems associated with aging.

HIV care providers are increasingly the point of access through which their clients access the healthcare system. We are expected to not only treat their chronic HIV diseases, but manage the total package of care and wellness, from routine health care maintenance to smoking cessation to age-appropriate cardiovascular and cancer screening to interventions designed to prevent onward transmission of HIV infection. And everything else in between. It is indeed a time of change for clinicians working in this field.

Supported by a number of federal, public and private agencies, this meeting is designed to address the team concept of HIV care. Dedicated clinicians have been integrally involved in planning ACTHIV and providers are the intended audience of this national conference. Certain ACTHIV sessions will utilize an electronic Audience Response System to encourage interaction and a dialogue among speakers and the participants. This year ACTHIV is presented with both single track plenary sessions and breakout sessions, allowing all attendees to maximize their participation in the entire meeting.

We look forward to meeting with you and to hearing your insights, along with your colleagues, in this vitally important field.

Sincerely,

Kathleen E. Squires, M.D.
Jefferson Medical College
Thomas Jefferson University

ACTHIV Program Committee Co-Chair

John T. Brooks, M.D.
Centers for Disease Control and Prevention

ACTHIV Program Committee Co-Chair
On behalf of the Board of Directors of The American Conference on the Treatment of HIV (ACTHIV),
WELCOME TO DENVER!

In September, 2005, the inaugural Conference on the Treatment and Management of HIV Infection in the United States was held in Atlanta, Georgia. This conference was a cooperative project of ten federal agencies involved in the care of HIV, and was a great success. Subsequent to that meeting it was decided that the conference should be independent of the government, and so the not-for-profit Foundation for The American Conference on the Treatment of HIV was created.

The first “ACTHIV” conference was held in May 2007 in Dallas, Texas and continued the precedent of a clinically oriented, state-of-the-art HIV conference. In 2009 we moved to Denver, and changed to annual instead of biennial meetings. Over the last year the foundation has worked with program co-chairs Kathleen Squires and John T. Brooks, the program committee, and a panel of co-operating federal agencies to put together this week’s third ACTHIV.

There are many conferences devoted to HIV, both national and international, but few of them are as uniquely focused on the clinical care of those living with HIV. ACTHIV is devoted to providing useful clinical information for those involved in frontline care of HIV. We hope that you will find the information presented at this conference beneficial in the day-to-day management and care of your patients.

Sincerely,

Douglas J. Ward, MD, FACP
President, Board of Directors
The American Conference on the Treatment of HIV
## Schedule at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Thursday, May 20</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 am – 6:00 pm</td>
<td>Registration Open</td>
<td>Centennial Foyer</td>
</tr>
<tr>
<td>1:00 pm – 4:30 pm</td>
<td>HIV: The Basics</td>
<td>Centennial A-B</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Friday, May 21</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 7:00 pm</td>
<td>Registration Open</td>
<td>Centennial Foyer</td>
</tr>
<tr>
<td>7:00 am – 8:30 am</td>
<td>Breakfast</td>
<td>Centennial Foyer</td>
</tr>
<tr>
<td>8:30 am – 10:00 am</td>
<td>Opening Plenary Session: HIV in the U.S. and Beyond: Where We’re Going</td>
<td>Centennial D</td>
</tr>
<tr>
<td>10:00 am – 7:00 pm</td>
<td>Exhibit Hall Open</td>
<td>Exhibit Hall, Centennial E-H</td>
</tr>
<tr>
<td>10:00 am – 10:30 am</td>
<td>Morning Refreshment Break</td>
<td>Exhibit Hall, Centennial E-H</td>
</tr>
<tr>
<td>10:30 am – 12:30 pm</td>
<td>Session 1: HIV Treatment</td>
<td>Centennial D</td>
</tr>
<tr>
<td>12:30 pm – 2:00 pm</td>
<td>Luncheon</td>
<td>Exhibit Hall, Centennial E-H</td>
</tr>
<tr>
<td>12:30 pm – 2:00 pm</td>
<td>Poster Sessions 1 &amp; 2</td>
<td>Exhibit Hall, Centennial E-H</td>
</tr>
</tbody>
</table>

Poster presenters from the following topics will be available for questions:
- Poster Session 1: The Treatment Experienced and Treatment Naïve Patient
- Poster Session 2: Co-Morbidities

<table>
<thead>
<tr>
<th>Time</th>
<th>Saturday, May 22</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 5:00 pm</td>
<td>Registration Open</td>
<td>Centennial Foyer</td>
</tr>
<tr>
<td>7:00 am – 8:30 am</td>
<td>Breakfast</td>
<td>Centennial Foyer</td>
</tr>
<tr>
<td>8:30 am – 10:00 am</td>
<td>Session 3: Special Challenges</td>
<td>Centennial D</td>
</tr>
<tr>
<td>10:00 am – 3:00 pm</td>
<td>Exhibit Hall Open</td>
<td>Exhibit Hall, Centennial E-H</td>
</tr>
<tr>
<td>10:00 am – 10:30 am</td>
<td>Morning Refreshment Break</td>
<td>Exhibit Hall, Centennial E-H</td>
</tr>
<tr>
<td>10:30 am – 11:30 am</td>
<td>Special Challenges Breakout Sessions:</td>
<td>See Below</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Sunday, May 23</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 9:00 am</td>
<td>Registration</td>
<td>Centennial Foyer</td>
</tr>
<tr>
<td>7:30 am – 9:00 am</td>
<td>Breakfast</td>
<td>Centennial Foyer</td>
</tr>
<tr>
<td>8:00 am – 9:30 am</td>
<td>Breakfast with the Experts (non-CME)</td>
<td>See below</td>
</tr>
</tbody>
</table>

- How to Start an HIV Practice
- Drug-Drug Interactions
- Interpreting Antiretroviral Drugs
- HIV in the VHA
Registration

Registration Services
Thursday through Sunday
Level 3, Centennial Foyer

Attendees who registered online may check-in at the registration desk and pick up all meeting materials, including badges and the conference program.

On–site registration will be open during the following hours:

Thursday, May 20  11:00 am – 6:00 pm
Friday, May 21   7:00 am – 7:00 pm
Saturday, May 22 7:00 am – 5:00 pm
Sunday, May 23  7:30 am - 9:00 am

Onsite Fees:
Registration fees include access to oral sessions, CME/CE credits, poster sessions, exhibit hall, breakfasts, lunches, breaks, reception, and one copy of the conference program.

Meal and Refreshments

Meeting registration includes all meals, receptions, and refreshments provided by ACTHIV 2010.

Continental Breakfast
Level 3, Exhibit Hall, Centennial Foyer
Friday, May 21  7:00 am – 8:30 am
Saturday, May 22 7:00 am – 8:30 am

Morning Refreshment Break
Level 3, Exhibit Hall, Centennial Ballroom E-H
Friday, May 22  10:00 am – 10:30 am
Saturday, May 23 10:00 am – 10:30 am

Lunch
Level 3, Exhibit Hall, Centennial Ballroom E-H
Friday, May 21  12:30 pm – 2:00 pm
Saturday, May 22 11:30 am – 1:00 pm

Afternoon Refreshment Break
Level 3, Centennial Foyer
Saturday, May 22  3:45 pm – 4:00 pm

Special Events

Welcome Reception
Level 3, Centennial Ballroom E-H
Friday, May 21  5:00 pm – 7:00 pm

Continental Breakfast (Breakfast with the Experts)
Level 3, Mineral Foyer
Sunday, May 23  7:30 am – 9:00 am

Meeting Registration*
Attendee  $300
Student  $225

*If you do not wish to apply for continuing education credits, $50.00 will be deducted at time of payment from your total registration fee.

Receipts
All who registered online should have received a receipt/confirmation via email. Participants who register onsite will receive a paper receipt only if requested; otherwise a confirmation email will be sent to the email address provided.

Badges
Badges should be worn at all official functions of the meeting. Badge checkers will be stationed throughout the meeting site. Only those with full meeting registrations will be allowed into sessions.

If you forget or lose your badge, you may obtain a second badge at registration with proof of registration.

Receipts
All who registered online should have received a receipt/confirmation via email. Participants who register onsite will receive a paper receipt only if requested; otherwise a confirmation email will be sent to the email address provided.

Badges
Badges should be worn at all official functions of the meeting. Badge checkers will be stationed throughout the meeting site. Only those with full meeting registrations will be allowed into sessions.

If you forget or lose your badge, you may obtain a second badge at registration with proof of registration.

*If you do not wish to apply for continuing education credits, $50.00 will be deducted at time of payment from your total registration fee.

Meeting Registration*
Attendee  $300
Student  $225

*If you do not wish to apply for continuing education credits, $50.00 will be deducted at time of payment from your total registration fee.

Receipts
All who registered online should have received a receipt/confirmation via email. Participants who register onsite will receive a paper receipt only if requested; otherwise a confirmation email will be sent to the email address provided.

Badges
Badges should be worn at all official functions of the meeting. Badge checkers will be stationed throughout the meeting site. Only those with full meeting registrations will be allowed into sessions.

If you forget or lose your badge, you may obtain a second badge at registration with proof of registration.

*If you do not wish to apply for continuing education credits, $50.00 will be deducted at time of payment from your total registration fee.

Receipts
All who registered online should have received a receipt/confirmation via email. Participants who register onsite will receive a paper receipt only if requested; otherwise a confirmation email will be sent to the email address provided.

Badges
Badges should be worn at all official functions of the meeting. Badge checkers will be stationed throughout the meeting site. Only those with full meeting registrations will be allowed into sessions.

If you forget or lose your badge, you may obtain a second badge at registration with proof of registration.

*If you do not wish to apply for continuing education credits, $50.00 will be deducted at time of payment from your total registration fee.

Receipts
All who registered online should have received a receipt/confirmation via email. Participants who register onsite will receive a paper receipt only if requested; otherwise a confirmation email will be sent to the email address provided.

Badges
Badges should be worn at all official functions of the meeting. Badge checkers will be stationed throughout the meeting site. Only those with full meeting registrations will be allowed into sessions.

If you forget or lose your badge, you may obtain a second badge at registration with proof of registration.

*If you do not wish to apply for continuing education credits, $50.00 will be deducted at time of payment from your total registration fee.

Receipts
All who registered online should have received a receipt/confirmation via email. Participants who register onsite will receive a paper receipt only if requested; otherwise a confirmation email will be sent to the email address provided.

Badges
Badges should be worn at all official functions of the meeting. Badge checkers will be stationed throughout the meeting site. Only those with full meeting registrations will be allowed into sessions.

If you forget or lose your badge, you may obtain a second badge at registration with proof of registration.

*If you do not wish to apply for continuing education credits, $50.00 will be deducted at time of payment from your total registration fee.

Receipts
All who registered online should have received a receipt/confirmation via email. Participants who register onsite will receive a paper receipt only if requested; otherwise a confirmation email will be sent to the email address provided.

Badges
Badges should be worn at all official functions of the meeting. Badge checkers will be stationed throughout the meeting site. Only those with full meeting registrations will be allowed into sessions.

If you forget or lose your badge, you may obtain a second badge at registration with proof of registration.

*If you do not wish to apply for continuing education credits, $50.00 will be deducted at time of payment from your total registration fee.

Receipts
All who registered online should have received a receipt/confirmation via email. Participants who register onsite will receive a paper receipt only if requested; otherwise a confirmation email will be sent to the email address provided.

Badges
Badges should be worn at all official functions of the meeting. Badge checkers will be stationed throughout the meeting site. Only those with full meeting registrations will be allowed into sessions.

If you forget or lose your badge, you may obtain a second badge at registration with proof of registration.

*If you do not wish to apply for continuing education credits, $50.00 will be deducted at time of payment from your total registration fee.

Receipts
All who registered online should have received a receipt/confirmation via email. Participants who register onsite will receive a paper receipt only if requested; otherwise a confirmation email will be sent to the email address provided.

Badges
Badges should be worn at all official functions of the meeting. Badge checkers will be stationed throughout the meeting site. Only those with full meeting registrations will be allowed into sessions.

If you forget or lose your badge, you may obtain a second badge at registration with proof of registration.

*If you do not wish to apply for continuing education credits, $50.00 will be deducted at time of payment from your total registration fee.
General Information

Accessibility for Registrants with Disabilities
The meeting staff will work with attendees to provide reasonable accommodations for those who require special needs. To request assistance on-site, please check in at the Registration Desk located on Level 3, Centennial Foyer.

Cameras, Recording Devices, and Cell Phones
The use of cameras, recorders and/or cell phones is strictly prohibited during the oral and poster sessions. Limited use is allowed for Exhibitors in their own booth area. Personal photography is allowed at social functions.

Cyber Café
Computer terminals with complimentary Internet access will be provided to all conference attendees. Terminals will be available for access in the Exhibit Hall during Exhibit Hall hours only. Access will be granted on a first come first served basis; however, as a courtesy to fellow meeting attendees, we ask that you limit your time at the computer to 10 minutes.

Business Center
The business center is located in the main lobby of the Hyatt Regency Denver, adjacent to the front desk. The center is equipped with photocopying and fax services, as well as Internet access and shipping services. Hours of operation are Monday through Friday from 7:00 am to 7:00 pm.

First Aid
The Hyatt Regency security team is first-aid/CPR trained and is reachable using any house phone and dialing 55. Perks, located on the lobby level of the Hyatt Regency Denver has all basic First Aid needs, including pain relievers and band-aids.

Hotels
ACTHIV 2010 has one participating hotel, the Hyatt Regency Denver.

Hyatt Regency Denver
650 15th Street,
Denver, Colorado, USA 80202
Phone: +1 (303) 436 – 1234
Fax: +1 (303) 486 – 4450

Lost & Found
Lost & Found will be located at the Registration Desk, located on Level 3, Centennial Foyer.

Message and Information Center
A message board will be located in the Registration area (Level 3, Centennial Foyer) for the duration of the conference. Should you need to reach a fellow attendee, please place a message on the board. Attendees will not be paged.

Print on Demand
A print on demand station will be available in the Centennial Foyer where you can download speaker presentations.

Additional Program Book
Each registrant receives one copy of the Conference Program Book. Additional copies will be provided at the conclusion of the conference and will be handed out on a first come first served basis. Please visit the Registration Desk for more information.

Transportation and Parking
There are a number of transportation options to and from the airport and in and around the city of Denver.

Yellow Cab
Phone: +1 (303) 777-7777
www.denveryellowcab.com
Estimated one-way cab fare to and from airport is $55.

Super Shuttle
Phone: +1 (303) 370-1300 | Toll Free: +1 (800) 258-3826
Website: http://www.supershuttledenver.com/
One-way fare from airport is $19.

Parking
The Hyatt Regency Denver has both valet and self parking options available. Please contact the hotel directly for the most up to date rates.

Rates are as follows:
Valet Parking
- Daily Valet Parking $18.00
- Overnight Valet Parking $28.00
Self-Parking
- Daily Self Parking $10.00 for first hour/
  $2.00 each additional hour
- Overnight Self Parking $24.00
Speakers Breakfast
A Speakers’ Breakfast as listed below will be held in Lime-
stone Level 4 of the Hyatt Regency Denver on Thursday and in Mineral A on Level 3 of the Hyatt Regency Denver. It is
crucial that speakers attend this very important breakfast
to meet with your Session Co-chairs and other presenters
within your session, and to learn about the audio visual
equipment and audience response system. A representative
of the American Academy of CME will also be on hand to
review CME/CE information with you, and answer any CME/
CE-related questions you may have.

Friday, May 21, 2010, 7:00 am – 8:00 am
HIV Treatment & Co-Morbidities:

Saturday, May 22, 7:00 am – 8:00 am
Special Challenges & Special Populations:

Speakers for HIV The Basics will meet in Centennial A/B on:
Thursday, May 20, 2010, 12:00 – 1:00.

Speaker Ready Room
Thursday Limestone
Friday through Saturday Mineral A

ALL Oral Presenters must check in at the Speaker Ready
Room at least four (4) hours prior to your scheduled presen-
tation to confirm that your presentation is correct.

When you are finished reviewing your presentation and
verify that it is ready, the AV personnel will queue your pre-
sentation onto the networked conference computers. The
file will then be transferred to the session computer prior
the start of your talk.

You may also edit your presentation at this time. Changes
will be accepted up to one (1) hour prior to the start of your
session. Please note that all changes must be approved by
the American Academy of CME, the accredited provider for
the conference.

The hours of operation of the Speaker Ready Room are as
follows:

Thursday, May 20 11:00 am – 6:00 pm
Friday, May 21 8:00 am – 7:00 pm
Saturday, May 22 8:00 am – 4:00 pm

Poster Presentations
Friday through Saturday
Exhibit Hall, Centennial Ballroom E-H

The Welcome Reception and all a.m. breaks and lunches will
take place in the Poster and Exhibit Hall area (Centennial
Ballroom E-H). We encourage presenters to stand next to
their poster during these high traffic times. We also ask that
each presenter stand next to their poster on the designated
day and time of their session to be available for questions.

The days and times are below:

Friday, May 21, 12:30 pm – 2:00 pm
Poster Session 1: The Treatment Experienced and
Treatment Naïve Patients

Poster Session 2: Co-Morbidities

Saturday, May 22, 11:30 am – 1:00 pm
Poster Session 3: Special Challenges
Poster Session 4: Special Populations

All posters must be set up between 4:00 pm and 6:00 pm on
Thursday, May 20 and 7:00 am – 9:00 am on Friday, May 21 in
Centennial Ballroom E-H at the Hyatt. The Poster Session and
Exhibit Hall will be open on Friday, May 21 from 10:00 am –
7:00 pm and Saturday, May 22 from 10:00 am – 3:00 pm.

All posters should remain on display through Saturday at
3:00 pm. Posters must be taken down between 3:00 pm and
5:00 pm on Saturday, May 22. Posters remaining after
5:00 pm on Saturday, May 22 will be discarded.
Physicians:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of CME (Academy) and ACTHIV. The Academy is accredited by the ACCME to provide continuing medical education for physicians.

The Academy designates this educational activity for a maximum of 15.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity has been reviewed and is acceptable for up to 15.50 Prescribed credits by the American Academy of Family Physicians.

Nurses:
American Academy of CME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Academy designates this educational activity for 15.5 contact hours. In order to receive your CE certificate, you must register for the conference, document attendance, and complete and return an evaluation form.

Pharmacists:
The American Academy of CME, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program provides 15.5 contact hours (1.55 CEUs) of continuing education credit. ACPE Universal Program Number [0297-9999-10-001-L-2-P]. In order to obtain your statement of credit, you must register for the conference, document attendance, and complete and return an evaluation form. A statement of credit will be mailed 6-8 weeks following the conference.

Social Workers:
This program is approved by the National Association of Social Workers (Provider #886476750) for 15.5 Continuing Education Contact Hours (with 2.5 of the 15.5 hours in the Substance Use Disorder Category).

How to Receive Credit
In order to receive your CME/CE documentation of credit, please sign-in during registration. After attending the conference, you must complete and return your evaluation form to the Accreditation Information Booth, located in the conference registration area (Level 3, Centennial Foyer). Documentation of credit will be distributed onsite, except for pharmacists, whose statements of credit will be mailed 6-8 weeks following the program. If you have questions about receiving CME/CE credit for participating in this activity, please visit the CME/CE Information Booth. For CME/CE information or credit details after the conference, contact emoylan@academycme.org or American Academy of CME, 1330 Route 206, Suite 103-600, Skillman, NJ 08558.

ANCC Accreditation Feedback
The Accreditation Program of the American Nurses Credentialing Center is interested in the opinions and perspectives of the participants in accredited continuing nursing education activities, particularly those perspectives related to the presence of perceived bias* in the continuing education. For this reason, we are now providing a toll free telephone number. Participants may access this number at any time to:
• tell us of any noted bias or conflict of interest in the education
• tell us of any concerns, compliments, or opinions
• tell us of a great experience
• tell us of an unpleasant experience
• tell us your thoughts on the process

Just call and tell us! 1-866-262-9730

*Bias is defined as: preferential influence that causes a distortion of opinion or of facts. Commercial bias may occur when an educational activity promotes one or more product(s) (drugs, devices, services, software, hardware etc.) This definition is not all inclusive and participants may use their own interpretation in deciding if a presentation is biased.

NOTE: Statements of commercial support and/or conflict of interest disclosures do not represent bias. Such statements inform the learner that the provider has implemented a mechanism to identify and resolve all conflicts of interest prior to delivery of the educational material.
Exhibit Hall Hours

Friday through Saturday
Level 3, Exhibit Hall, Centennial Ballroom E-H

The Exhibit Hall will be open during the following hours:

Friday, May 21  10:00 am – 7:00 pm
Saturday, May 22  10:00 am – 3:00 pm

Exhibitors

The following is a list of exhibits as of May 5, 2010:

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AETC National Resource Center</td>
<td>207</td>
</tr>
<tr>
<td>Association of Nurses in AIDS Care</td>
<td>103</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>308</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>406</td>
</tr>
<tr>
<td>HIV Medicine Association (HIVMA)</td>
<td>402</td>
</tr>
<tr>
<td>Merck</td>
<td>201</td>
</tr>
<tr>
<td>National HIV/AIDS Clinicians’ Consultation Center</td>
<td>309</td>
</tr>
<tr>
<td>National Institute of Health AIDS Research Programs</td>
<td>300</td>
</tr>
<tr>
<td>National Quality Center</td>
<td>203</td>
</tr>
<tr>
<td>Office of Public Health: Public Health Strategic Healthcare Group</td>
<td>200 and 202</td>
</tr>
<tr>
<td>TARGET Center</td>
<td>400</td>
</tr>
<tr>
<td>The Peter Schick Foundation</td>
<td>408</td>
</tr>
<tr>
<td>Tibotec Therapeutics</td>
<td>301</td>
</tr>
<tr>
<td>ViiV Healthcare</td>
<td>209</td>
</tr>
</tbody>
</table>

Detailed information about each of the exhibitors above as well as an exhibit hall floor plan can be found in the Support Supplement.
Thursday, May 20

11:00 am – 6:00 pm  Registration Open  Centennial Foyer

1:00 pm – 4:30 pm  HIV: THE BASICS  Centennial A-B

Session Co-Chairs:  
Brian Feit, MPA, Department of Health and Human Services  
Paul Volberding, MD, San Francisco VA Medical Center

1:10 pm – 1:30 pm  History of the Epidemic  
Paul Volberding, MD, San Francisco VA Medical Center

1:30 pm – 2:00 pm  Natural History of HIV Infection—Pathogenesis  
Melanie Thompson, MD, AIDS Research Consortium of Atlanta

2:00 pm – 2:30 pm  Clinical Tests & Guidelines  
Zelalem Temesgen, MD, Mayo Clinic

2:30 pm – 3:00 pm  Q&A

3:00 pm – 3:30 pm  Medications - Types of Antiretrovirals  
Roy Gulick, MD, Weill Medical College of Cornell University

3:30 pm – 4:00 pm  Drug Interaction  
Courtney Fletcher, PharmD, University of Nebraska Medical Center

4:00 pm – 4:30 pm  Consumer Perspective  
Ebony Johnson, MHS, Community Advocacy, Education & Empowerment Specialist

4:00 pm – 6:00 pm  Poster Set-up  Exhibit Hall, Centennial E-H

Friday, May 21

7:00 am – 7:00 pm  Registration Open  Centennial Foyer

7:00 am – 8:30 am  Breakfast  Centennial Foyer

8:30 am – 10:00 am  Opening Plenary Session  Centennial D

Session Co-Chairs:  
Kathleen Squires, MD, Co-chair, 2010 ACTHIV and Jefferson Medical College, Thomas Jefferson University  
John T. Brooks, MD, Co-chair, 2010 ACTHIV and Centers for Disease Control and Prevention

8:30 am – 8:55 am.  Opening Remarks  
John T. Brooks, MD, Centers for Disease Control and Prevention

8:55 am – 9:40 am  HIV in the US in 2010 and Beyond – Where We’re Going  
Michael Horberg, MD, Kaiser Permanente
Conference Agenda

Friday, May 21 (continued)

9:40 am – 10:00 am  Closing Remarks
  Kathleen Squires, MD, Co-chair, 2010 ACTHIV and Jefferson Medical College,
  Thomas Jefferson University

10:00 am – 10:30 am  Morning Refreshment Break

10:30 am – 12:30 pm  Session 1: HIV Treatment
  Session Co-Chairs:
  William R. Short, MD, MPH, Jefferson Medical College, Thomas Jefferson University
  Harry Lampiris, MD, San Francisco VA Medical Center/UCSF
  10:30 am – 11:00 am  When to Start, What to Start – Focusing on the New guidelines
    Monica Gandhi, MD, MPH, University of California, San Francisco
  11:00 am – 11:30 am  Engagement and Retention in Care
    Cody Poerio, MPH, Drexel University
  11:30 am – 12:00 pm  PEP, PREP Cases and ARVs to Decrease HIV Transmission
    Moupali Das, MD, MPH, San Department of Public Health
  12:00 pm – 12:30 pm  Cases in Treatment Experienced Patients
    All Speakers and Co-Chairs panel

12:30 pm – 2:00 pm  Luncheon

12:30 pm – 2:00 pm  Poster Presentations
  Poster presenters from the following topics will be available for questions:
    Poster Session 1 – The Treatment Experienced and Treatment Naive Patient
    Poster Session 2 – Co-Morbidities

2:00 pm – 5:10 pm  Session 2: Co-Morbidities
  Session Co-Chairs:
  Sharon Lee, MD, Family Health Care Services of Greater Kansas City
  Laura Armas-Kolostroubs, MD, Texas/Oklahoma AIDS Education and Training Center
  2:00 pm – 2:05 pm  Introduction
  2:05 pm – 2:50 pm  Immune-Regulation and T-cell Activation in HIV Disease
    Peter Hunt, MD, University of California, San Francisco
  2:50 pm – 3:15 pm  Cardiovascular Disease and HIV
    Kenneth Lichtenstein, MD, National Jewish Health
  3:15 pm – 3:40 pm  Neuropsychiatric Effects of HIV
    Eileen Martin, PhD, University of Illinois
  3:40 pm – 3:50 pm  Break
  3:50 pm – 4:15 pm  HIV-1 and Kidney Disease
    Mohamed Atta, MD, MPH, Johns Hopkins School of Medicine
  4:10 pm – 4:35 pm  Hepatitis in HIV
    Kenneth Sherman, MD, University of Cincinnati
  4:40 pm – 5:10 pm  Questions and Answers
### Friday, May 21 (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 pm – 7:00 pm</td>
<td>Welcome Reception</td>
<td>Centennial E-H</td>
</tr>
</tbody>
</table>

### Saturday, May 22

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 5:00 pm</td>
<td>Registration Open</td>
<td>Centennial Foyer</td>
</tr>
<tr>
<td>7:00 am – 8:30 am</td>
<td>Breakfast</td>
<td>Centennial Foyer</td>
</tr>
<tr>
<td>8:30 am – 11:30 am</td>
<td>Session 3: Special Challenges</td>
<td>Centennial D</td>
</tr>
<tr>
<td></td>
<td><strong>Session Co-Chairs:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Erika Aaron, CRNP, MSN,</em> Drexel University College of Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Melanie Thompson, MD,</em> AIDS Research Consortium of Atlanta</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Lisa Fitzpatrick, MD, MPH,</em> Howard University</td>
<td></td>
</tr>
<tr>
<td>8:30 am - 9:00 am</td>
<td>HIV and Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Roger Bedimo, MD, MS, FACP,</em> VA North Texas Health Care System</td>
<td></td>
</tr>
<tr>
<td>9:00 am – 9:30 am</td>
<td>Psychiatric/Mental Illness</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>David Rubenstein, PsyD,</em> Rowan University</td>
<td></td>
</tr>
<tr>
<td>9:30 am – 10:00 am</td>
<td>Addiction in the Setting of HIV</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Harout Tossonian, MD, PhD,</em> University of British Columbia</td>
<td></td>
</tr>
<tr>
<td>10:00 am – 3:00 pm</td>
<td>Exhibit Hall Open</td>
<td>Exhibit Hall, Centennial E-H</td>
</tr>
<tr>
<td>10:00 am – 10:30 am</td>
<td>Morning Refreshment Break</td>
<td>Centennial E-H</td>
</tr>
<tr>
<td>10:30 a.m. – 11:30 am</td>
<td>Special Challenges Breakout Sessions</td>
<td>Centennial E-H</td>
</tr>
</tbody>
</table>

**Breakout 1: Reproductive Health**

*Jean Anderson, MD, FACOG,* Johns Hopkins Medicine
*Erika Aaron, CRNP, MSN,* Drexel University College of Medicine

**Breakout 2: Aging**

*Sally Hodder, MD,* University of Medicine & Dentistry New Jersey

**Breakout 3: Smoking Cessation**

*Alvaro Carrascal, MD, MPH,* AIDS Institute, New York Department of Health

**Breakout 4: Adherence/Linkage to Care**

*Ken George, PharmD,* Drexel University College of Medicine

**Breakout 5: STD in the HIV-Infected Population**

*Laura Bachmann, MD, MPH,* Wake Forest University
*Baptist Medical Center
Saturday, May 22 (continued)

Breakout 6: HIV and Testing
Donna Futterman, MD, *Albert Einstein College of Medicine*

11:30 am – 1:00 pm  Luncheon  Exhibit Hall, Centennial E-H

11:30 am – 1:00 pm  Poster Sessions 3 & 4

Poster presenters from the following topics will be available for questions:

Poster Session 3: Special Challenges
Poster Session 4: Special Populations

1:00 pm – 3:45 pm  Session 4: Special Populations

Session Co-Chairs:  
*Tonia Poteat, MMSc, MPH, PA-C, Chase Brexton Health Services*  
*Donna Futterman, MD, Albert Einstein College of Medicine*  
*Christopher Gordon, PhD, National Institutes of Health*  
*Anita Radix, MD, MPH, Callen Lorde Community Health Center*

1:00 pm – 1:30 pm  Overview
Speaker:  
*David Kim, MD, Centers for Disease Control and Prevention*

1:30 pm – 1:45 pm  Afternoon Refreshment Break

1:45 pm – 3:45 pm  Special Populations Breakout Sessions

Breakout 1: Homeless/Incarcerated/Immigrant  
Cari Courtenay-Quirk, PhD, *Centers for Disease Control and Prevention*  (Homeless)
Brian Montague, DO, MS, MPH, *Brown University*  (Incarcerated)
Laura Armas-Kolostroubis, MD, *Texas/Oklahoma AIDS Education and Training Center*  (Immigrant)

Breakout 2: MSM/Transgender/Adolescent  
Alex Gonzalez, MD, MPH, *Fenway Health*  (MSM)
Anita Radix, MD, MPH, *Callen Lorde Community Health Center*  (Transgender)
Donna Futterman, MD, *Albert Einstein College of Medicine*  (Adolescent)

3:45 pm – 5:00 pm  Closing Plenary - HIV and Aging  
Session Chair:  
*Sharon Lee, MD, Family Health Care Services of Greater Kansas City*

3:45 pm – 3:50 pm  Introduction
Sharon Lee, MD, *Family Health Care Services of Greater Kansas City*
Saturday, May 22 (continued)

3:50 pm – 4:20 pm  The Aging Epidemiology of HIV in the US - VA Study  
Amy Justice, MD, PhD, Department of Veterans Affairs

4:20 pm – 4:50 pm  The Pathology of Immunsenescence Associated with HIV  
Steve Deeks, MD, University of California, San Francisco

4:50 – 5:00 pm  Q&A and Close

Sunday, May 23

8:00 am – 9:30 am  Breakfast with the Experts  
(Please note that these sessions are non-CME qualified)  
Attendees are encouraged to submit questions or case studies for the presenter by 5:00 pm. on Friday, May 21st. Questions or case studies can be dropped off at the registration desk.  
A continental breakfast will be supplied in Centennial Foyer by 7:30 a.m. You may pick up your breakfast and proceed to the appropriate meeting room. Please arrive to your session on time.

How to Start an HIV Practice  
Moderator: Sharon Lee, MD, Family Health Care Services of Greater Kansas City

Interpreting AntiRetroviral Drug Resistance Results  
Moderator: Kathleen Squires, MD, Jefferson Medical College, Thomas Jefferson University

Drug-Drug Interactions  
Moderator: Alice Pau, PharmD, National Institute of Allergy and Infectious Diseases, NIH

HIV in VHA:  Working Together to Improve Testing, Care and Prevention  
Moderators: David Ross, MD, PHD, U.S. Department of Veterans Affairs  
Janet Durfee, RN, MSN, APRN, US. Department of Veterans Affairs
The Program Committee has invited frontline healthcare professionals who directly providers care to persons living with HIV, or who are part of a multidisciplinary team providing care for persons living with HIV to submit papers for consideration in the poster program. The papers that were selected for posters describe creative approaches to treatment adherence, outreach to special populations (e.g. homelessness, transgenders) and co-morbidities.

Poster presenters will be available for discussion during the following session times:

**Friday, May 21, 12:30 pm – 2:00 pm**
Poster Session 1: The Treatment Naïve and Treatment Experienced Patients
Poster Session 2: Co-Morbidities

**Saturday, May 22, 11:30 am – 1:00 pm**
Poster Session 3: Special Challenges
Poster Session 4: Special Populations

NOTE: CME/CE credit is not available for participation in the Poster Session.

### Poster Session 1 & 2 - Friday, May 21

**TEP - 1**
Two Cases of B Cell Lymphoma in HIV-positive Patients Presenting as Low Back Pain
Olga Ali, South Texas Veterans Health Care System, Gregory Anstead, MD, South Texas Veterans Health Care System

**TEP - 2**
Renal Toxicity of Long-Term Therapy with Tenofovir in HIV-Infected Patients
Maricelle Monteagudo-Chu, PharmD, Bronx VA Medical Center, Norbert Brau, MD, Bronx VA Medical Center, Mei Chang, PharmD, Bronx VA Medical Center, Horatio Fung, PharmD, Bronx VA Medical Center

**TEN - 1**
Boosted Protease Inhibitors as Sole Agents for Selected HIV Infected Patients: Sometimes Less is Enough
Michael Cynamon MD, VA Medical Center

**TEP - 3**
Assessing the Association Between HIV-related Knowledge and Clinical Outcomes among HIV-Infected Patients
Surina Gupta, MD, VA Medical Center and Baylor College of Medicine, Maria Rodriguez-Barradas, MD, VAMC and Baylor College of Medicine, Barbara Trautner, MD, VAMC and Baylor College of Medicine, Aanand Naik, MD, VAMC and Baylor College of Medicine, N. Petersen, VAMC and Baylor College of Medicine, A. Garza, VAMC and Baylor College of Medicine, M.O. Nakawah, VAMC and Baylor College of Medicine, Thomas Giordano, MD, VAMC and Baylor College of Medicine

**COM - 1**
Decreasing Incidence and Changing Epidemiology of Herpes Zoster in the HAART Era
David Rimland, MD, Atlanta VA Medical Center, Jodie Guest, PhD, Atlanta VA Medical Center, Brittany Hill, MPH, Atlanta VA Medical Center
CONFERENCE PROGRAM

Poster Sessions

COM - 2 Evaluation of the Safety and Efficacy of Atorvastatin and Rosuvastatin for the Treatment of Dyslipidemia in HIV Patients with NNRTI based HAART Therapy
Anjali Patel, PharmD, VA North Texas Health Care System, Susan Duquaine, PharmD, VA North Texas Health Care System, Roger Bedimo, MD, VA North Texas Health Care System, Henning Drechsler, MD, VA North Texas Health Care System, Kevin Kelly, PharmD VA North Texas Health Care System

COM - 3 Pharmacotherapeutics of the HIV-infected Elderly with Co-morbidities: Emphasis on Drug-drug Interactions
Tina Edmunds-Ogbaruokiri, BSc, PharmD, HIV Outpatient Program, Marco Ruíz, MD, HIV Outpatient Program, Ceryl Lynn Besch, MD, HIV Outpatient Program

COM - 4 Optimizing Care of the HIV-infected Elderly with Depression and Other Co-morbidities: Emphasis on Drug-Drug Interactions
Tina Edmunds-Ogbaruokiri, BSc, PharmD, HIV Outpatient Program, Marco Ruíz, MD, HIV Outpatient Program, Ceryl Lynn Besch, MD, HIV Outpatient Program

COM - 5 An Introduction to the AIDS Education and Training Centers
Andrea Norberg, MS, AETC National Resource Center, Jamie Steiger, MPH, AETC National Resource Center

COM - 6 Evaluating the Management of Diabetes Mellitus Type-2 in HIV-infected Patients
Agnes Cha, PharmD, The Brooklyn Hospital Center, Evangelina Berrios-Colon, PharmD, The Brooklyn Hospital Center, Leonard Berkowitz, MD, The Brooklyn Hospital Center

Poster Session 3 & 4 - Saturday, May 22

SPC - 1 Implementation of Nurse-Based HIV Rapid Testing in VA Substance Use Disorder Clinics
Erin Conners, MPH, West Los Angeles VA, Henry Anaya, West Los Angeles VA, Herschel Knapp, West Los Angeles VA, Hildi Hagedorn, Minneapolis VA, Jaimi Butler, West Los Angeles VA

SPC - 2 Invasive Squamous Cell Carcinoma of the Penis in HIV-infected Men: Report of 3 Cases

SPC - 3 The Successful Treatment of Wide Spread Life-threatening Kaposi Sarcoma.
Melissa Chase, PharmD, VA Central California Health Care System, Donald Tayloe, MD, VA Central California Health Care System

SPC - 4 Multi-Regional Evaluation of a Program to Promote HIV Testing

SPC - 5 CHECK YOURSELF - “Normalising HIV Testing Through Football”
Esther Mosinghi, MHP, Community Development Organisation, George Parolalista, BA, George Alexander Group, Beatrice Nabulya, MS, Community Development Organisation

SPC - 6 HIV Psychology: Mental Health Integration and Co-location
Maggie Chartier, PsyD, MPH, San Francisco VA Medical Center, Timothy Carmody, PhD San Francisco VA Medical Center, Harry Lampiris, MD, San Francisco VA Medical Center

SPC - 7 Project SHALEM: Engagement of the Faith Based Community in HIV Testing
Derek Spencer, MSN, University of Maryland School of Medicine, Jamie Mignano, MSN, University of Maryland School of Medicine

SPC - 8 National Level Capacity Building Initiative: A Survey to Assess Consumer Involvement in HIV Programs to Improve HIV Care in the United States
Daniel Tietz, MPH, AIDS Institute, Meera Vohra, MPH, National Quality Center, Lennie Green, BS, National Quality Center Consumer Advisory Committee, Judith Billings, National Quality Center Consumer Advisory Committee, Clemens Steinbock, MBA, National Quality Center, Graciela Carrasco, BA, National Quality Center
Poster Sessions

Poster Session 3 & 4 - Saturday, May 22

**SPC - 9** Group Work for Heterosexual Couples of Mixed HIV Status
Jeanne Saporito, MSW, Bronx VA Medical Center

**SPC - 10** The JACQUES Initiative: Integrated Testing and Linkage to Care
Derek Spencer, MSN, University of Maryland School of Medicine, Jamie Migonno, MSN, University of Maryland School of Medicine

**SPC - 11** Community Outreach in Support of HIV Testing for Homeless Veterans
Linda Allen, MSW, VA Medical Center-DC, Melissa Turner, LICSW, VA Medical Center

**SPC - 12** A Clinic Model: Care of Pregnant Women with HIV Infection
Richa Tandon, MD, Boston University School of Medicine, Helene Hardy, PharmD, MSc, Boston University School of Medicine, Jennifer Dwan, MD, Boston University School of Medicine, Stephen Pelton, MD, Boston University School of Medicine, Jennifer Dwan, MD, Boston University School of Medicine, Stephen Pelton, MD, Boston University School of Medicine, Jennifer Dwan, MD, Boston University School of Medicine

**SPC - 13** Herpes Folliculitis Masquerading as CA-MRSA (A Very Unusual Presentation of a Common Disease)
Aysha Khalid, MD, Kansas University Hospital, Kassem Hammoud, Kansas University Hospital, Daniel Hinthorn, Kansas University Hospital

**SPP - 1** Tertiary Healthcare Utilization Among Indigent HIV-Positive Adults: the Role of Homelessness, Stimulant Use, and Depression
Maggie Chartier, PsyD, MPH, San Francisco VA Medical Center, Carrico Adam, PhD, Center for AIDS Prevention Studies, UCSF, Sheri Weiser, MD, University of California, San Francisco, Elise Riley, PhD, Center for AIDS Prevention Studies, UCSF

**SPP - 2** Primary Care Assessment of Transgendered Persons: Implications for HIV Clinics and Community Health Centers
Linda Rose Frank, PhD, University of Pittsburgh

**SPP - 3** An Evaluation Of The HIV Clinical Pharmacy Consultant Monitoring Program within the Federal Bureau of Prisons
Michael Dupree, PharmD, Federal Bureau of Prisons, Jim Britton, PharmD, Federal Bureau of Prisons
Faculty

Erika Aaron, MSN
Division of Infectious Diseases and HIV Medicine
Drexel University College of Medicine

Jean Anderson, MD
Department of Gynecology and Obstetrics
Johns Hopkins Medical Institutions

Laura Armas-Kolostroubis, MD
Texas/Oklahoma AIDS Education and Training Center

Mohamed Atta, MD
Division of Nephrology
Johns Hopkins School of Medicine

Laura Bachmann, MD
WG (Bill) Hefner Medical Center
Wake Forest University Health Sciences

Alvaro Carrascal, MD
AIDS Institute
New York State Department of Health

Cari Courtenay-Quirk, PhD
Division of HIV/AIDS Prevention Centers for Disease Control and Prevention

Moupali Das, MD
HIV/AIDS and ID Divisions
University of California, San Francisco

Steve Deeks, MD
University of California, San Francisco

Janet Durfee, RN, MSN, APRN
U.S. Department of Veterans Affairs

Courtney Fletcher, PharmD
College of Pharmacy
University of Nebraska Medical Center

Donna Futtermann, MD
Albert Einstein College of Medicine
Montefiore Medical Center

Monica Gandhi, MD
Divisions of HIV/AIDS and Infectious Diseases
University of California, San Francisco

Ken George, PharmD
Drexel University College of Medicine

Alex Gonzalez, MD
Fenway Health

Roy M. Gulick, MD
Division of Infectious Diseases
Weill Medical College of Cornell University

Sally Hodder, MD
University of Medicine & Dentistry of New Jersey

Michael Horberg, MD
Kaiser Permanente

Peter Hunt, MD
Department of Medicine
University of California, San Francisco

Ebony P. Johnson, MHS
Community Advocacy
A Drop of Prevention, LLC.

Amy Justice, MD
West Haven VA Healthcare System

David Kim, MD
Division of HIV/AIDS Prevention Centers for Disease Control and Prevention

Harry Llampiris, MD
San Francisco VA Medical Center
University of California, San Francisco

Sharon Lee, MD
Department of Family Medicine
Southwest Boulevard Family Health Care Services of Greater Kansas City

Kenneth A. Lichtenstein, MD
HIV Clinical and Research Program
National Jewish Health

Eileen Martin, PhD
Department of Psychiatry
University of Illinois

Brian Montague, DO, MS, MPH
Division of Infectious Diseases
Brown University/The Miriam Hospital

Alice Pau, PharmD
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Cody Poerio, MPH
College of Medicine
Drexel University

Anita Radix, MD
Callen Lorde Community Health Center

David Ross, MD, PhD
U.S. Department of Veterans Affairs

David Rubenstein, PsyD, MSW
Counseling and Psychological Services
Rowan University

Kenneth Sherman, MD
Division of Digestive Diseases
University of Cincinnati

Kathleen Squires, MD
Jefferson Medical College
Thomas Jefferson University

Zelalem Temesgen, MD
Division of Infectious Diseases
Mayo Clinic

Melanie Thompson, MD
AIDS Research Consortium of Atlanta

Harout Tossonian, MD, PhD
University of British Columbia

Paul Volberding, MD
Department of Medicine
San Francisco VA Medical Center
**Financial and Off Label Usage Disclosures**

**Program Committee and Session Co-Chairs**

**Erika Aaron, CRNP, MSN**, has no relevant financial disclosure to make.

**Laura Armas-Kolostroubis, MD**, has no relevant financial disclosure to make.

**Arlene Bardeguez, MD, MPH**, discloses that she is an officer/board member of the HIV Medical Association.

**John T. Brooks, MD**, has no relevant financial disclosure to make.

**Steven Deeks, MD**, discloses that he has received research funding Bristol-Myers Squibb, Gilead Sciences, Merck & Co, and Pfizer, and that all of these funds were paid to University of California, San Francisco.

**Lisa Fitzpatrick, MD, MPH**, has no relevant financial disclosure to make.

**Donna Futterman, MD**, was the PI on educational grants from Gilead Sciences and Inverness, and the funds were paid to Montefiore Medical Center.

**Harold Henderson, MD**, has no relevant financial disclosure to make.

**John JD Juchniewicz, MCIS**, has no relevant financial disclosure to make.

**Natalie Kirkwood, RN, BS, JD**, has no relevant financial disclosure to make.

**Harry Lampiris, MD**, discloses he has received grant research support from Adamas Pharmaceuticals, Gilead Sciences (PI), Pfizer (PI), and the funds were paid to Northern California Institute for Research and Education (NCIRE).

**Sharon Lee, MD**, has no relevant financial disclosure to make.

**Kenneth Lichtenstein, MD**, discloses he has served on the advisory boards for scientific information for Bristol-Myers Squibb, Gilead Sciences, and Schering-Plough. He has received grant research support from Gilead Sciences, Merck & Co (PI), Pfizer, and TailMed, and the funds were paid to National Jewish Health. He has served on the promotional speakers’ bureau of Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, and Merck & Co.

**Tonia Poteat, MMSc, MPH, PA-C**, has no relevant financial disclosure to make.

**M. Keith Rawlings, MD**, discloses he has been a member of the advisory boards for scientific information and marketing purposes for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, and Tibotec. He is a member of the promotional speaker’s bureaus of Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, and Triptoc.

**David Rimland, MD**, discloses he has received grant research support (local PI) from Pfizer, and the funds were paid to Atlanta Research and Education Foundation.

**William Short, MD**, has served on the promotional speakers’ bureaus for Gilead Sciences, Merck & Co, and Tibotec.

**Kathleen E. Squires, MD**, discloses that she served on advisory boards for scientific information for Gilead Sciences, Merck & Co, Schering-Plough, Tibotec, and Tobira Therapeutics, and for marketing purposes for Gilead Sciences, GlaxoSmithKline and Tobotec. She has served as a consultant related to clinical trials for GlaxoSmithKline, Merck & Co, and Tibotec. She has received grant research support for which she was the PI from Gilead Sciences, GlaxoSmithKline, Merck & Co, Schering Plough, and Tibotec, and the funds were paid to Thomas Jefferson University.

**Melanie Thompson, MD**, Melanie Thompson, MD, discloses she has served on scientific advisory boards or as a consultant for clinical trial design for Chimerix, GlaxoSmithKline, Panacos Pharmaceuticals (now Myriad), Progens Pharmaceuticals, and Tibotec. She has received grant research support from Abbot Laboratories, Avexa, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Kattketsukai, Merck Research Laboratories, Ora-Sure, Panacos Pharmaceuticals, Pfizer, Progens Pharmaceuticals, Roche Laboratories, Roche Molecular Systems, Theratechnologies, Tibotec and Tobira Therapeutics. She has served on data safety monitoring boards for Tibotec.

**Glenn Treisman, MD, PhD**, has served on the promotional speakers’ bureau of Boehringer Ingelheim.

**Douglass Ward, MD**, discloses he has served on advisory boards for scientific information and/or marketing purposes for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViIV Healthcare (GlaxoSmithKline), and Tibotec. He has received grant research support for which he was the PI from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Merck & Co, Schering-Plough, and ViIV Healthcare (GlaxoSmithKline and Pfizer), and the funds were paid to Dupont Circle Physicians Group. He has served on the promotional speaker’s bureaus for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Merck & Co, Monogram Biosciences, and ViIV Healthcare (GlaxoSmithKline and Pfizer).

**Barbara A. Young, MSW, LCSW, LCADC, SAC**, has no relevant financial disclosure to make.
Financial and Off Label Usage Disclosures

Federal Scientific Collaborative Panel

Songhai Barcliff, MD, has no relevant financial disclosure to make.

Gina Brown, MD, has no relevant financial disclosure to make.

Laura Cheever, MD, has no relevant financial disclosure to make.

Robert Eisinger, PhD, has no relevant financial disclosure to make.

Brian Feit, MPA, has no relevant financial disclosure to make.

Christopher Gordon, PhD, has no relevant financial disclosure to make.

Newton Kendig, RADM, has no relevant financial disclosure to make.

Jag Khalsa, PhD, has no relevant financial disclosure to make.

Peter Kim, MD, has no relevant financial disclosure to make.

Lynne Mofenson, MD, has no relevant financial disclosure to make.

Mostafa Nokta, MD, MPH, has no relevant financial disclosure to make.

Ronald Valdiserri, MD, MPH, has no relevant financial disclosure to make.

Paul Volberding, MD, discloses he has served on the advisory boards for scientific information for Bristol-Myers Squibb and Gilead Sciences. He has served as a consultant for clinical trial design (data safety monitoring board) for Merck & Co.

Faculty

Jean Anderson, MD, has served on the advisory board for scientific information for Tibotec. She has received funding from Abbott for the printing of a provider tool developed for preconception care. Dr. Anderson does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Laura Armas-Kolostroubis, MD, has no relevant financial disclosure to make. Dr. Armas-Kolostroubis does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Erika Aaron, MSN, ANP, CRNP, has no relevant financial disclosure to make. Ms. Aaron does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Mohamed G. Atta, MD, MPH, has no relevant financial disclosure to make. Dr. Atta does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Laura H. Bachmann, MD, MPH, has no relevant financial disclosure to make. Dr. Bachmann intends to discuss oral and rectal testing for N. gonorrhoeae and C. trachomatis with Gen-Probe APTIMA Combo 2®, BDProbeTec™ ET, and Roche COBAS® PCR; and testing for T. vaginalis utilizing Gen-Probe APTIMA Combo 2® and Roche COBAS® Amplicor PCR.

Roger Bedimo, MD, MS, discloses he has served on advisory boards for scientific information for EMD Serono, Gilead Sciences, Merck & Co., and Tibotec. He has received grant research support from Merck & Co (PI) and Tibotec (PI), and the funds were paid to The Dallas VA Research Corporation (DVARC). Dr. Bedimo does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

John Brooks, MD, has no relevant financial disclosure to make. Dr. Brooks does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Alvaro Carrascal, MD, MPH, has no relevant financial disclosure to make. Dr. Carrascal does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Cari Courtenay-Quirk, PhD, has no relevant financial disclosure to make. Dr. Courtenay-Quirk does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Mostafa Nokta, MD, MPH, has no relevant financial disclosure to make.

Ronald Valdiserri, MD, MPH, has no relevant financial disclosure to make.

Paul Volberding, MD, discloses he has served on the advisory boards for scientific information for Bristol-Myers Squibb and Gilead Sciences. He has served as a consultant for clinical trial design (data safety monitoring board) for Merck & Co.

Donna Futterman, MD, was the PI on educational grants from Gilead Sciences and Inverness, and the funds were paid to Montefiore Medical Center. Dr. Futterman does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Monica Gandhi, MD, has no relevant disclosures to make. Dr. Gandhi does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Kenneth George, PharmD, BCPS, has no relevant disclosures to make. Dr. George does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.
Faculty (continued)

Alex Gonzalez, MD, MPH, has no relevant disclosures to make. Dr. Gonzalez does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Amy C. Justice, MD, PhD, has no relevant disclosures to make. Dr. Justice does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Anita Radix MD, MPH, discloses she has served on the promotional speakers’ bureau of GlaxoSmithKline. Dr. Radix intends to discuss cross gender hormone therapy.

David F. Rubenstein, PsyD, MSW, has no relevant disclosures to make. Dr. Rubenstein does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Kathleen E. Squires, MD, discloses that she served on advisory boards for scientific information for Gilead Sciences, Merck & Co, and Vertex Pharmaceuticals. She has served on end point adjudication committees for Pfizer and Tibotec. Clinical research funding has been received from Anadys (PI), Bristol-Myers Squibb (PI), Gilead Sciences (PI), Human Genome Sciences, Roche (PI), Schering-Plough (PI), SciClone, and Vertex, which was paid to the University of Cincinnati and/or University Internal Medicine Associates/University of Cincinnati Physicians. He has intellectual property/patents that were assigned to the US Army. Dr. Sherman intends to discuss the use of directly acting antiviral (DAA) agents for HCV and HBV.

Roy M. Gulick, MD, discloses he has served as a consultant for clinical trial design for Bristol-Myers Squibb, Gilead Sciences, Medimmune, and Virostatrics. He has received grant/research support from Pfizer (PI), Schering-Plough (PI) Tibotec, and Wyeth, and the funds were paid to Weill Medical College of Cornell University. Dr. Gulick intends to discuss investigational antiretroviral agents in his presentation.

Roy M. Gulick, MD, discloses he has served as a consultant for clinical trial design for Bristol-Myers Squibb, Gilead Sciences, Medimmune, and Virostatrics. He has received grant/research support from Pfizer (PI), Schering-Plough (PI) Tibotec, and Wyeth, and the funds were paid to Weill Medical College of Cornell University. Dr. Gulick intends to discuss investigational antiretroviral agents in his presentation.

Peter W. Hunt, MD, discloses that he has served on the advisory board for scientific information for Merck & Co. He has received grant research support from Pfizer (PI), and the funds were paid to University of California, San Francisco. Dr. Hunt does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Peter W. Hunt, DO, MS, MPH, has no relevant disclosures to make. Dr. Montague does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Cody J. Poerio, MPH, has no relevant disclosures to make. Mr. Cody does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Ebony Johnson, MHS, has no relevant disclosures to make. Ms. Johnson does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Sally Hodder, MD, discloses she has been an advisor for scientific information for Boehringer Ingelheim, Gilead Sciences, and Tibotec. She has been a consultant for scientific publication for Tibotec. She has received grant research support from Gilead Sciences (PI) and Tibotec (PI), and the funds were paid to University of Medicine & Dentistry of New Jersey. Her spouse is an officer/board member of Becton Dickinson, and is a retired employee of Merck & Co. who holds stock options in his former employer. Dr. Hodder intends to discuss the use of atorvastatin for the prevention of cardiovascular disease in persons with normal cholesterol.

Michael Horberg, MD, discloses he has received grant research support Merck & Co, and Pfizer, and the grants were paid to the Kaiser Foundation Research Institute. Dr. Horberg does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Michael Horberg, MD, discloses he has received grant research support Merck & Co, and Pfizer, and the grants were paid to the Kaiser Foundation Research Institute. Dr. Horberg does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

David Kim, MD, MA, has no relevant disclosures to make. Dr. Kim does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Sharon Lee, MD, has no relevant financial disclosure to make. Dr. Lee does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Kenneth Lichtenstein, MD, discloses has served on the advisory boards for scientific information for Bristol-Myers Squibb, Gilead Sciences and Schering-Plough, and for marketing for Merck and GlaxoSmithKline. He has served as a consultant on clinical trial design for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck & Co, and Schering-Plough. He has received grant research support from Gilead Sciences, Merck & Co (PI), Pfizer, and TaiMed, and the funds were paid to National Jewish Health. He has served on the promotional speakers’ bureaus of Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences and Merck & Co. Dr. Lichtenstein does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Eileen M. Martin, PhD, has no relevant disclosures to make. Dr. Martin does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Kenneth Sherman, MD, has served on the advisory boards for scientific information for Anadys, Bristol-Myers Squibb, Merck & Co, and Vertex Pharmaceuticals. He has been a consultant for clinical trial design for SciClone Pharmaceuticals and Valeant Pharmaceuticals. He has served on end point adjudication committees for Pfizer and Tibotec. Clinical research funding has been received from Anadys (PI), Bristol-Myers Squibb (PI), Gilead Sciences (PI), Human Genome Sciences, Roche (PI), Schering-Plough (PI), SciClone, and Vertex, which was paid to the University of Cincinnati and/or University Internal Medicine Associates/University of Cincinnati Physicians. He has intellectual property/patents that were assigned to the US Army. Dr. Sherman intends to discuss the use of directly acting antiviral (DAA) agents for HCV and HBV.

Kathleen Squires, MD, discloses that she served on advisory boards for scientific information for Gilead Sciences, Merck & Co, Schering-Plough, Tibotec, and Tobira Therapeutics, and for marketing purposes for Gilead Sciences, GlaxoSmithKline and Tibotec. She has served as a consultant related to clinical trials for GlaxoSmithKline, Merck & Co, and Tibotec. She has received grant research support for which she was the PI from Gilead Sciences, GlaxoSmithKline, Merck & Co, Schering Plough, and Tibotec, and the funds were paid to Thomas Jefferson University. Dr. Squires does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Zelalem Temesgen, MD, discloses he has served on advisory boards for scientific information for Boehringer Ingelheim, Gilead Sciences, Medimmune, and Virostatrics. He has received grant/research support from Pfizer (PI), Schering-Plough (PI) Tibotec, and Wyeth, and the funds were paid to Weill Medical College of Cornell University. Dr. Gulick intends to discuss investigational antiretroviral agents in his presentation.
Financial and Off Label Usage Disclosures

Faculty (continued)

information for Gilead Sciences and Merck & Co. He has received grant research support (PI) from Pfizer, and educational grants from Gilead Sciences and Tibotec Therapeutics. The funds related to these grants were paid to his institution and a portion of these funds were used to support his and his study coordinator’s salaries. Dr. Temesgen does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Melanie Thompson, MD, discloses she has served on scientific advisory boards or as a consultant for clinical trial design for Chimerix, GlaxoSmithKline, Panacos Pharmaceuticals (now Myriad), Progenics Pharmaceuticals, and Tibotec. She has received grant research support from Abbot Laboratories, Avexa, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Katketsuken, Merck Research Laboratories, Ora-Sure, Panacos Pharmaceuticals, Pfizer, Progenics Pharmaceuticals, Roche Laboratories, Roche Molecular Systems, Theratechnologies, Tibotec and Tobira Therapeutics. She has served on data safety monitoring boards for Tibotec. Dr. Thompson does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Harout Tossonian, MD, PhD, has no relevant disclosures to make. Dr. Tossonian does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.

Paul Volberding, MD, discloses he has served on the advisory boards for scientific information for Bristol-Myers Squibb and Gilead Sciences. He has served as a consultant for clinical trial design (data safety monitoring board) for Merck & Co. Dr. Volberding does not intend to discuss any non-FDA-approved or investigational uses of any products/devices.